{"product_id":"hygeia-group-pestle-analysis","title":"Hygeia PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Smarter Strategic Decisions with a Complete PESTEL View\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how political shifts, economic pressures, social trends, technological advances, legal changes, and environmental risks are shaping Hygeia’s strategic path in our concise PESTLE snapshot. Ideal for investors and strategists, it highlights actionable risks and opportunities. Buy the full PESTLE for a detailed, ready-to-use briefing you can download instantly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNational health policy priorities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eChina’s Healthy China 2030 and oncology drives channel capital and screening programs—China recorded about 4.6 million new cancer cases in 2020 (GLOBOCAN) and recent NRDL updates (2020–23) added multiple oncology drugs with price cuts up to ~70%, unlocking reimbursement and approvals. Alignment with these policies can secure land, approvals and funding; shifts may reallocate budgets between prevention and tertiary care, so continuous policy monitoring is essential for Hygeia’s network planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicensing and approvals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHospital establishment, bed quotas and radiotherapy equipment require multi-level approvals, with timelines reported to range from 6 to 24 months across provinces, impacting rollout speed. Provincial variance in criteria and documentation creates uneven approval rates and can push project timelines. Strong local government relationships have been shown to reduce regulatory friction and expedite permits. Delays frequently inflate pre-opening costs and defer revenue, often adding a double-digit percentage to initial CAPEX.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic–private collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePublic–private partnership models and entrusted management are viable tools to expand oncology capacity, linking private investment with public hospitals to meet rising demand driven by 19.3 million global cancer cases in 2020 (Globocan). Terms hinge on local fiscal priorities, risk-sharing and oversight; favorable deals can secure patient flows and land access. Governance requires rigorous KPI reporting and compliance controls to protect public interest.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare funding and reimbursement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCentral and provincial reimbursement policies drive patient affordability for cancer care, shaping demand for Hygeia services and out-of-pocket exposure. DRG\/DIP payment reforms shift hospitals toward bundled payments, altering service mix and compressing margins on high-cost oncology care. Explicit inclusion of radiotherapy in benefit packages increases utilization and capital planning, while public budget constraints can lengthen settlement cycles with hospital partners.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReimbursement scope: determines patient access\u003c\/li\u003e\n\u003cli\u003eDRG\/DIP: impacts margins and service mix\u003c\/li\u003e\n\u003cli\u003eRadiotherapy coverage: raises utilization\u003c\/li\u003e\n\u003cli\u003eBudget caps: risk longer hospital settlements\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitics and supply security\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGeopolitics and export controls since 2022 have tightened access to advanced radiotherapy components, contributing to a 6–8% supply delay rate in 2023–24 for high-end LINAC parts; trade tensions and local substitution policies in EU and China are accelerating domestic sourcing, with China-targeted localization rising ~15% yr\/yr in 2024.\u003c\/p\u003e\n\u003cp\u003eCurrency swings—EUR\/USD and USD\/CNY moved ~8–12% 2023–2024—raised imported device costs materially, increasing BOM costs by an estimated 3–5% for Hygeia; strategic inventory buffers and dual-sourcing reduced disruption-related revenue loss in peers by ~30% in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExport controls constrain advanced components\u003c\/li\u003e\n\u003cli\u003eLocal substitution up ~15% (2024)\u003c\/li\u003e\n\u003cli\u003eFX moves 8–12% (2023–24) → BOM +3–5%\u003c\/li\u003e\n\u003cli\u003eStrategic inventory\/dual-sourcing cut losses ~30%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolicy shifts and approval delays reshape China oncology access and pre-opening costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHealthy China 2030 and NRDL updates (4.6M new cancer cases 2020; price cuts up to ~70%) drive reimbursement access but require constant policy tracking. Approvals for hospitals\/equipment vary 6–24 months, raising pre-opening CAPEX. Export controls caused 6–8% LINAC part delays (2023–24); FX moves 8–12% (2023–24) raised BOM ~3–5%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eReimbursement\u003c\/td\u003e\n\u003ctd\u003e4.6M cases; NRDL cuts ≤70%\u003c\/td\u003e\n\u003ctd\u003eHigher demand, lower OOP\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApprovals\u003c\/td\u003e\n\u003ctd\u003e6–24 months\u003c\/td\u003e\n\u003ctd\u003eDelay CAPEX\/revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupply\/FX\u003c\/td\u003e\n\u003ctd\u003eDelays 6–8%; FX 8–12%\u003c\/td\u003e\n\u003ctd\u003eBOM +3–5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect Hygeia across Political, Economic, Social, Technological, Environmental and Legal dimensions, with each section backed by current data and trend analysis to identify threats and opportunities for executives, investors and strategists.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, visually segmented Hygeia PESTLE summary that can be dropped into presentations, annotated for local context, and easily shared across teams to streamline external risk discussions and strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMacroeconomic growth and cycles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSlower GDP growth (global ~3.0% in 2024; IMF forecast ~3.1% in 2025) compresses public health budgets and private payer demand, with OECD health spending growth slowing to ~1.6% recently. Oncology demand remains relatively non-cyclical, but capex cycles affect timing of high-cost oncology equipment purchases. Regional disparities require tiered pricing and phased expansion; counter-cyclical services like diagnostics (≈30% of hospital revenue) stabilize cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAging demographics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eChina’s aging trend—65+ roughly 15% of the population—drives higher cancer incidence, with about 4.6 million new cancer cases annually, sustaining demand for oncology services. Longer lifespans (life expectancy ~78 years) expand follow-up and adjuvant therapy volumes. Service planning must anticipate complex comorbidities and scale workforce and bed capacity accordingly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReimbursement mix and affordability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eReimbursement mix—formal urban employee schemes (covering roughly 5–10% of Nigerians) versus informal resident households drives ARPU, with employer plans yielding higher per-patient revenue. Out-of-pocket remains very high (around 70–75% of health spending per World Bank), suppressing uptake of advanced modalities. Charity funds and commercial riders (penetration \u0026lt;5%) can expand access. Pricing must balance subsidized rates with ROI on costly equipment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital intensity and depreciation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRadiotherapy centers need heavy upfront capex: LINACs typically cost 2–5 million USD and shielding\/build-out 0.5–2 million USD; long asset lives (10–15 years) produce high depreciation and steady maintenance charges. Utilization (commonly 60–80%) drives returns and payback (often 5–10 years); financing costs and tax depreciation rules (2024–25 interest environment ~4–8%) materially change IRR.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCAPEX: LINAC 2–5M, site 0.5–2M\u003c\/li\u003e\n\u003cli\u003eAsset life: 10–15 yrs → high depreciation\u003c\/li\u003e\n\u003cli\u003eUtilization: 60–80% → payback 5–10 yrs\u003c\/li\u003e\n\u003cli\u003eFinancing\/tax: 2024–25 rates ~4–8% → significant IRR impact\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUrban–rural market dynamics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eTier 1\/2 cities deliver higher payor density and quicker revenue capture but face stiffer competition and higher capex per facility; urbanization is 56% globally (UN DESA 2022). Lower-tier markets show growth potential with thinner payer coverage; global cancer burden was ~19.3 million new cases in 2020 (IARC), guiding site selection toward local epidemiology and income. Referral networks and hub-and-spoke models optimize case mix and utilization.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePayor density: higher in Tier 1\/2; faster ROI\u003c\/li\u003e\n\u003cli\u003eCompetition: elevated capex and staffing costs\u003c\/li\u003e\n\u003cli\u003eLower-tier: growth but lower insurance penetration\u003c\/li\u003e\n\u003cli\u003eSite selection: align with local income + cancer incidence\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolicy shifts and approval delays reshape China oncology access and pre-opening costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSlower global GDP (~3.0% 2024; IMF ~3.1% 2025) and OECD health spending growth (~1.6%) compress budgets; oncology stays resilient but capex timing matters. China aging (65+ ~15%) and ~4.6M new cancers sustain demand; OOP remains high (70–75%), limiting uptake of advanced care. LINAC capex 2–5M USD, site 0.5–2M; utilization 60–80% drives 5–10 yr payback; financing ~4–8% impacts IRR.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal GDP growth\u003c\/td\u003e\n\u003ctd\u003e~3.0% (2024), ~3.1% (2025 IMF)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOECD health spend growth\u003c\/td\u003e\n\u003ctd\u003e~1.6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChina 65+\u003c\/td\u003e\n\u003ctd\u003e~15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChina new cancers\u003c\/td\u003e\n\u003ctd\u003e~4.6M\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOOP health spend\u003c\/td\u003e\n\u003ctd\u003e70–75%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLINAC capex\u003c\/td\u003e\n\u003ctd\u003e2–5M; site 0.5–2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUtilization\/payback\u003c\/td\u003e\n\u003ctd\u003e60–80% → 5–10 yrs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancing rates\u003c\/td\u003e\n\u003ctd\u003e~4–8% (2024–25)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eHygeia PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact document you’ll receive after purchase—fully formatted and ready to use. The Hygeia PESTLE Analysis contains comprehensive political, economic, social, technological, legal and environmental assessments tailored to healthcare and pharma strategy. No placeholders or teasers—this is the final, professionally structured file available for instant download.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":55675430601081,"sku":"hygeia-group-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/hygeia-group-pestle-analysis.png?v=1755808414","url":"https:\/\/portersfiveforce.com\/products\/hygeia-group-pestle-analysis","provider":"Porter's Five Forces","version":"1.0","type":"link"}